Investigational drug · Phase 2
nC-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for CHRONIC HYPONATREMIA.
Phase 2Last checked: Nov 19, 2026Latest source record: May 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "nC-001"
First trial start
2025
Aug 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "nC-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- CHRONIC HYPONATREMIA
Largest trials
Live from ClinicalTrials.gov: studies naming "nC-001" as an intervention, largest first.
- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)Completed
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT01215851 · 85 participants · Start Oct 2010 · Primary completion May 2011
Drug: PA-824; Pyrazinamide and 3 more · For: Pulmonary Tuberculosis
Sites: Cape Town, South Africa · 2 sites in all
- Phase 2a Study for PK/PD of nC-001Not yet recruiting
nephCentricIndustry
NCT06798675 · 24 participants (planned) · Start Aug 2025 · Primary completion Mar 2026
Drug: nC-001; Placebo · For: CHRONIC HYPONATREMIA
Newest research
PubMed records naming it or its code names, newest first.
- Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approach.
de Castro Suarez N, Nuermberger EL, Ernest J, et al. · bioRxiv 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.